logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Lymphoma Follicular

    FiltersReset Filters
    9 results

    • brukinsa

      (zanubrutinib)
      BEIGENE USA, INC.
      Usage: BRUKINSA is indicated for treating adult patients with mantle cell lymphoma, Waldenström's macroglobulinemia, relapsed or refractory marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed or refractory follicular lymphoma in combination with obinutuzumab, after prior therapies.

    • epkinly

      (epcoritamab-bysp)
      Genmab US, Inc.
      Usage: EPKINLY is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after two or more systemic therapies, as well as for relapsed or refractory follicular lymphoma (FL) after similar treatment. Approval is based on response rates and durability.

    • gazyva

      (obinutuzumab)
      Genentech, Inc.
      Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.

    • lenalidomide

      (Lenalidomide)
      Biocon Pharma Inc.
      Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.

    • lenalidomide

      (lenalidomide)
      Cipla USA Inc.
      Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.

    • lunsumio

      (Mosunetuzumab)
      Genentech, Inc.
      Usage: LUNSUMIO is indicated for adult patients with relapsed or refractory follicular lymphoma following two or more lines of systemic therapy. Its approval is based on response rates and may require further verification of clinical benefit in confirmatory trials.

    • revlimid

      (Lenalidomide)
      Celgene Corporation
      Usage: REVLIMID is indicated for adult patients with multiple myeloma (MM), myelodysplastic syndromes (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). It is used in combination with dexamethasone, rituximab products, or as maintenance therapy post-transplant. Not recommended for chronic lymphocytic leukemia (CLL).

    • rituxan hycela

      (rituximab and hyaluronidase)
      Genentech, Inc.
      Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.

    • tazverik

      (tazemetostat)
      Epizyme, Inc.
      Usage: TAZVERIK is indicated for adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. It is also indicated for adults with relapsed or refractory follicular lymphoma positive for an EZH2 mutation after at least 2 prior therapies or lacking satisfactory alternatives.